2024 Revenues ($USD) : $16.54B

Teva Pharmaceutical Industries Ltd. put up revenues of $16.5 billion for the full year 2024, a 6% increase in local currency terms compared to 2023. This marked its second consecutive year of top-line growth and capped off seven straight quarters of gains by year-end.

Looking inside the numbers, its portfolio showed some bright spots in 2024. AUSTEDO (deutetrabenazine) pulled in revenues north of $1.6 billion, beating expectations. AJOVY (fremanezumab) generated $507 million globally, an 18% bump in local currency, and UZEDY (risperidone extended-release injectable suspension) landed at $117 million, also topping its $100 million target.

The generics side of the house also contributed, posting growth across its major markets in 2024 (local currency vs 2023): up 15% in the U.S., 6% in Europe, and 15% in International Markets. Notable generic launches during the year included the first copy of Sandostatin LAR Depot and an authorized generic of Victoza. More recently, in January 2025, Teva inked a licensing and supply deal for a potential generic GLP-1 product. Its biosimilar efforts seem to be moving along too, reporting 18 assets in the pipeline and anticipating the U.S. launch of SELARSDI, its ustekinumab biosimilar, in the first quarter of 2025.

On the R&D front, Teva flagged positive Phase 3 results from the SOLARIS trial for TEV-‘749 (olanzapine), its investigational once-monthly subcutaneous long-acting injectable aimed at schizophrenia. Interestingly, a survey during the trial suggested high patient satisfaction (over 92% satisfied/very satisfied). The company leaned into this patient-centric theme when presenting data from its schizophrenia portfolio at the SIRS congress in March 2025.